Chris H Takimoto
CIK 1743780 · CHIEF MEDICAL OFFICER · last filed 2026-01-21
"Disclosed insider exposure" sums this person's most-recently-reported share counts across each company they're an insider in, multiplied by the current underlying price. It is not net worth — it misses retail holdings, private investments, real estate, index funds, and any company where the person isn't an SEC-reporting insider. For informational purposes only.
Charts
Trading activity, where the exposure sits, and each trade against the stock price.
FTSV price and trades
Daily close with each Form 4 filing on this company marked: green = open-market buy, red = open-market sale, purple = grants, exercises, gifts and other non-market transactions. Marker size scales with the dollar value.
Shares held
Shares owned after each reported transaction on this company (direct holdings as reported).
Open-market buying and selling
by monthDollar value of open-market purchases (code P, up) and sales (code S, down) across all companies, by filing month. Grants, exercises and gifts are excluded.
Exposure by company
latestMost recently reported shares × current price. Faded bars (*) have had no filing in 3 years, so the person may no longer hold them. Click a bar to chart that company.
Filer Profile
325 E. MIDDLEFIELD ROAD
MOUNTAIN VIEW, CA 94043
Holdings By Company
| Symbol | Role | Shares | Price | Disclosed Exposure | Lifetime OM Net | Filings | Latest Filed |
|---|---|---|---|---|---|---|---|
| ALXO | Director | — | $1.19 | — | $0 | 2 | 2026-01-21 |
| IGM Biosciences, Inc. (IGMS) Delisted | CHIEF MEDICAL OFFICER | 154,331 | $1.27 | $196.0K | -$277.4K | 17 | 2024-09-17 |
| Forty Seven, Inc. (FTSV) Delisted | Chief Medical Officer | 0 | — | — | -$8.90M | 12 | 2020-04-07 |
Recent Filings · Page 2 of 4
32 filings| Filed | Symbol | Action | Net Shares | Net $ | Link |
|---|---|---|---|---|---|
| 2023-04-06 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | +26,250 | $0 | EDGAR |
| 2023-03-16 | IGM Biosciences, Inc. (IGMS) Delisted | Sell (S) | −1,768 | -$33.1K | EDGAR |
| 2022-12-20 | IGM Biosciences, Inc. (IGMS) Delisted | Sell (S) | −5,430 | -$103.1K | EDGAR |
| 2022-11-28 | IGM Biosciences, Inc. (IGMS) Delisted | Sell (S) | −877 | -$18.9K | EDGAR |
| 2022-05-26 | IGM Biosciences, Inc. (IGMS) Delisted | Sell (S) | −938 | -$16.0K | EDGAR |
| 2022-05-17 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | +825 | $10.2K | EDGAR |
| 2022-03-17 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | +14,477 | $0 | EDGAR |
| 2022-03-15 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | +12,500 | $0 | EDGAR |
| 2021-11-19 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | +10,000 | $0 | EDGAR |
| 2021-08-03 | IGM Biosciences, Inc. (IGMS) Delisted | Grant (A) | — | $0 | EDGAR |
Notice (144 / 144/A): Form 144 is a notice of intent to sell restricted/control stock under Rule 144, filed before the sale; 144/A is an amendment. Many notices are pre-scheduled under Rule 10b5-1 plans. A Form 4 with code S typically follows within a few days when the planned sale executes; missing follow-up Form 4s suggest the notice was cancelled or modified.